ImmunoCellular Therapeutics Appoints Gary S. Titus to its Board of Directors

  ImmunoCellular Therapeutics Appoints Gary S. Titus to its Board of Directors

Business Wire

LOS ANGELES -- January 2, 2013

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today
announced the appointment of Gary S. Titus to its board of directors. Mr.
Titus is currently the Senior Vice President and Chief Financial Officer of
SciClone Pharmaceuticals, Inc. and has more than 20 years of business
experience in the healthcare and biopharmaceutical industries. Mr. Titus has
extensive experience in working with public corporations in a variety of
areas, including financial planning and analysis, SEC reporting, investor
relations, business development, and corporate strategy.

“Gary’s strategic financial planning skills, strong commitment to fiscal
responsibility and regulatory compliance and broad financial leadership
experience in both R&D-based and commercial operating companies make him an
ideal addition to ImmunoCellular’s board of directors,” said Andrew Gengos,
Chief Executive Officer. “Gary’s reputation for integrity and thoughtful
analysis complement his broad management and planning skill set, and will be
especially valuable as we advance our pipeline, expand our business and
strengthen our position as a leading cancer immunotherapy company.”

In September 2012, Jacqueline Brandwynne stepped down from ImmunoCellular’s
board of directors. John Yu, MD, PhD, Founder, Chief Scientific Officer and
Chairman of the Board commented: “We look forward to Gary’s valuable
contribution to the financial health and corporate leadership of our company.
We also want to acknowledge the significant contribution to our company from
Jacqui throughout her tenure as a valued and respected member of our board. We
thank her for her tireless work on our behalf, her integrity and her 'can-do'
attitude. She gave generously of her time and provided wise counsel that
benefitted our company. We will miss her, and wish her well.”

Mr. Titus has held the position of Chief Financial Officer at SciClone since
2008. Prior to SciClone, Mr. Titus served as Senior Vice President of Finance
and Chief Financial Officer at Kosan Biosciences, prior to its acquisition by
Bristol-Myers Squibb, in which transaction he played a significant role. Prior
to that, Mr. Titus was Chief Financial Officer and Vice President at Nuvelo,
Inc. Earlier in his career, Mr. Titus held a variety of positions with
increasing management responsibilities at other companies, including
Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc., and Johnson & Johnson’s
healthcare division LifeScan, Inc. Mr. Titus earned a Bachelor of Science
degree in Accounting from University of South Florida and a Bachelor of
Science degree in Finance from University of Florida and is a Certified Public
Accountant. He also completed the Global BioExecutive Program at UC Berkeley’s
Haas School of Business and is a member of several professional organizations.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage
company that is developing immune-based therapies for the treatment of brain
and other cancers. ImmunoCellular has commenced a Phase II trial of its lead
product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple
tumor-associated antigens for glioblastoma. To learn more about
ImmunoCellular, please visit www.imuc.com.

Contact:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415-348-0010 direct
415-652-4819 mobile
jane@jmgcomm.com
 
Press spacebar to pause and continue. Press esc to stop.